SCHEMBL14270127

SCHEMBL14270127

[N-]=[N+]=N[C@H](CO)C(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CES1 P23141 2/20 0.45
▸ CA1 P00915 2/20 0.44
▸ CA2 P00918 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ SLC6A2 P23975 1/20 0.43
▸ SLC6A4 P31645 1/20 0.43
▸ SLC6A3 Q01959 1/20 0.43
▸ GSK3B P49841 1/20 0.43
▸ ALDH1A1 P00352 3/20 0.42
▸ TSHR P16473 2/20 0.42
▸ MAPK1 P28482 1/20 0.42
▸ L3MBTL1 Q9Y468 1/20 0.42
▸ CES2 O00748 1/20 0.41
▸ SRD5A2 P31213 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ MEN1 O00255 2/20 0.40
▸ KMT2A Q03164 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20817113 0.75 ALDH1A1 (0.45) TDP1ALDH1A1TSHRMAPK1L3MBTL1
SCHEMBL16788843 0.74 CYP2C19 (0.44) CA2TDP1ALDH1A1TSHRL3MBTL1
SCHEMBL16092975 0.74 CYP2C19 (0.44) CA2TDP1ALDH1A1TSHRL3MBTL1
SCHEMBL16092976 0.73 ALDH1A1 (0.45) TDP1ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL16788844 0.73 ALDH1A1 (0.45) TDP1ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL14270257 0.73 LMNA (0.45) TDP1ALDH1A1TSHRL3MBTL1MAPT
SCHEMBL14270275 0.72 LMNA (0.47) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL16788837 0.72 LMNA (0.47) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL14022413 0.72 LMNA (0.47) ALDH1A1TSHRMAPTMEN1KMT2A
SCHEMBL14270314 0.71 MEN1 (0.52) CA1CA2ALDH1A1TSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same BioVersys AG (CH) 2008-02-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045585-A1 Macrocyclic Compounds And Methods Of Making And Using The Same VIP, PROKR1, PGC CES1 2670/4885CA1 2393/4885CA2 3768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback